相关实验视频

Updated: May 24, 2025

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

基因组信息化药物重定位策略确定了代谢功能障碍相关的稳态性肝病的新疗法标

Hannah M Seagle^1,2,3,4, Alexis T Akerele^1,5,6, Joseph A DeCorte^7,8

¹Vanderbilt University Genetics Institute, Department of Medicine, Vanderbilt University, Nashville, Tennessee, United States of America.

medRxiv : the preprint server for health sciences

|March 4, 2025

概括

药物再利用提供了有效的疾病治疗. 这项研究确定了代谢功能障碍相关的脂肪性肝病 (MASLD) 的新型遗传标,建议icosapent ethyl和fingolimod作为潜在的治疗方法.

科学领域:

遗传学是一个遗传学.
药理学药理学是指药理学的学科.
肝病学肝病学是一种肝病学.

背景情况:

与代谢功能障碍相关的脂肪性肝病 (MASLD) 对健康造成重大负担.
确定MASLD的有效治疗方法对于患者的治疗结果至关重要.
药物重定向为开发新疗法提供了一种具有成本效益的战略.

研究的目的:

为了确定新的,基因支持的药物标,用于MASLD.
评估现有药物用于MASLD治疗的治疗潜力.

主要方法:

利用跨学科的方法,整合遗传关联数据,途径分析和蛋白质结构建模.
分析了一项大型的多祖先遗传关联研究,以确定MASLD的因果基因.
采用孟德尔的随机化来评估药物标的疗效.

主要成果:

确定了212个MASLD的潜在因果基因,其中158个 (74.5%) 是新鲜的.
确定了57个可用药物的蛋白质标,其中药物的作用与MASLD风险的遗传预测保持一致.
发现了强有力的证据表明icosapent乙烯激活FADS1和fingolimod针对S1PR2作为潜在的MASLD治疗方法.

结论:

这项研究提出了一种强大的方法,用于识别复杂疾病的药物重定向候选人,如MASLD.
通过icosapent ethyl激活FADS1和通过fingolimod激活S1PR2显示为MASLD的新疗法战略.
这项研究有助于开发更高效,更有效的MASLD治疗方法.

关键词:

药物重新使用的药物.马斯尔德马斯尔德是什么意思门德尔的随机化这是NAFLD.转录组广泛的关联研究研究.

更多相关视频

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

相关概念视频

Drug Biotransformation: Overview

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...